Drug Profile
SCO 094
Alternative Names: SCO-094; TAK-094Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Takeda
- Developer SCOHIA PHARMA
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Obesity in Japan
- 28 Sep 2023 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in United Kingdom (SC)
- 17 Aug 2022 Scohia Pharma completes a phase-I trial in Type 2 diabetes mellitus in United Kingdom (SC) (JapicCTI-205323)